* European Medicines Agency Committee Classifies Advaxis’
Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom…
The post BRIEF-EMA classifies Advaxis cervical cancer drug as an ‘advanced-therapy medicinal product’ appeared first on NASDAQ.